The incidence, natural history, biology, and treatment of transformed lymphomas.

  title={The incidence, natural history, biology, and treatment of transformed lymphomas.},
  author={Steven H. Bernstein and W Richard Burack},
  journal={Hematology. American Society of Hematology. Education Program},
Treatment of patients with transformed lymphoma presents a significant challenge to the practicing physician. Indeed, the transformation of follicular lymphoma to a more aggressive histology is inherent to the biology of this disease and is often associated with an aggressive clinical course, resulting in a poor prognosis. Recent population-based studies have better defined the incidence of this event, and recent laboratory studies have defined the molecular and immunological processes… 

Tables from this paper

Management of Patients With Histologic Transformation.

  • N. Reddy
  • Medicine
    Clinical lymphoma, myeloma & leukemia
  • 2017

Guidelines of the Belgian hamatological Society for newly diagnosed and relapsed follicular lymphoma 2012.

The introduction of rituximab in the treatment regimen has changed the picture of the disease, and resulted in an increase of progression-free survival.

Transformed Follicular Lymphoma: Not all fit in one

The present review describes the state of art of tFL, outlining recent advances in the understanding of genetic basis and the evolutionary pro-cess governing the initiation and persistence of tumor evolution.

A rare case of follicular lymphoma transformed to a high‐grade B‐cell lymphoma in orbit

Histological transformation in patients with follicular lymphoma who were previously treated with immune‐chemotherapy carry a poor outcome, and a case with aggressive histological transformation from a low‐grade lymphoma is illustrated.

Treatment Outcome in Patients with Primary or Secondary Transformed Indolent B-Cell Lymphomas

The outcome of treatment in pHT cases is favorable and significantly better than in sHT cases, and response to treatment for transformation was highly prognostic of PFS and OS.

Guidelines of the Belgian Hematological Society for newly diagnosed and relapsed follicular lymphoma anno 2019 PRACTICE GUIDELINES

An update of the scientific evidence regarding diagnosis, staging, treatment and follow-up, and confront these to the Belgian reimbursement rules anno 2019 is presented.

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy

This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types.

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.

  • A. MeyerA. Stroux C. Scholz
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2014
It is demonstrated that transformation into aggressive lymphoma, as well as additional malignancies, are important independent risk factors for a shortened OS in a multivariate analysis, irrespective of the MZL localization.

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

BCL2 mutations can affect antiapoptotic Bcl-2 function, are associated with increased activation-induced cytidine deaminase expression, and correlate with increased risk of transformation and death due to lymphoma.



Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.

Transformation is an early event in the course of the disease and is mainly observed in patients with known adverse prognostic factors or those who do not achieve CR after initial treatment, and may be useful to select follicular lymphoma patients for intensive therapeutic approaches.

The natural history of initially untreated low-grade non-Hodgkin's lymphomas.

The actuarial risk of transformation among the initially untreated patients was similar to that in a group of patients treated at this institution immediately after diagnosis, and the time to histologic transformation nor the incidence of transformation was influenced by when therapy was started.

Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma.

In rituximab-naive patients with indolent lymphoma, the addition of ritUXimab to CHOP chemotherapy significantly improves overall survival after transformation.

The Architecural Pattern of FOXP3+ T Cells Predicts Risk of Transformation in Patients with Follicular Lymphoma (FL).

Treg cell distribution within the tumor is an important predictor of Tly in advanced-stage FL patients treated uniformly with an aggressive treatment regimen and reinforces the importance of a FOXP3 follicular pattern as a good surrogate for functionally active Treg cellswithin the tumor microenvironment.

Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.

  • A. Al-TourahK. Gill J. Connors
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Clinically diagnosed transformation has an equal impact on outcome as biopsy proven transformation, and advanced stage at diagnosis is predictive of future transformation.

Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.

  • A. GlasL. Knoops D. de Jong
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
The identification of FL as an immunologically functional disease in which an interaction of the tumor cells and the functional composition of the microenvironment determines the clinical behavior is supported.

Transformation of follicular lymphoma to diffuse large B‐cell lymphoma proceeds by distinct oncogenic mechanisms

T‐FL is a germinal centre B (GCB‐like malignancy that evolves by two pathways, one that is similar in proliferation rate to the antecedent FL and the other that has a higher proliferation rate and is characterised by the presence of recognised oncogenic abnormalities.

The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.

FLIPI and histology were the most important variables predicting HT, and only patients achieving CR reached prolonged survival, thus emphasizing the need for effective therapies once this event occurs.

Histologic conversion in the non-Hodgkin's lymphomas.

Documented histologic conversion was often associated with a more aggressive clinical behavior of the lymphoma, and the median survival after conversion was less than 1 yr, however, those patients who achieved a CR after conversion had a more favorable outcome.

Long-term survival after histologic transformation of low-grade follicular lymphoma.

A subset of patients with HT from low-grade follicular lymphoma to intermediate- or high-grade lymphoma enjoys relatively long-term survival and patients with limited disease and no previous exposure to chemotherapy have the most favorable prognosis.